Pharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringe
CT‑P39 AI was pharmacokinetically equivalent to EU-OMA PFS following a single dose in healthy Japanese individuals; pharmacodynamics, safety, and immunogenicity were comparable.
Authors
- Clive Grattan (ORCID: https://orcid.org/0000-0002-8466-4351)
- Rie Yazawa
- Michio Yagi
- Yunju Bae
- Sarbjit S. Saini (ORCID: https://orcid.org/0000-0001-8522-2742)
- Sunghyun Kim (ORCID: https://orcid.org/0000-0002-4791-1376)
- Jong‐Ho Kim (ORCID: https://orcid.org/0000-0001-6256-7713)
- Su‐Young Kim (ORCID: https://orcid.org/0000-0002-3251-5813)
- Jeong Eun Park
- Takashi Eto
- Tomoko Hasunuma
Institutions
- Guy's Hospital (GB)
- SOUSEIKAI Global Clinical Research Center (JP)
- Kitasato Institute Hospital (JP)
- Celltrion (South Korea) (KR)
- Kitasato University (JP)
Publication Details
- Journal
- Immunotherapy
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1080/1750743x.2025.2467026
- Citations
- 1
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.80